Myriad Genetics, Inc

MYGNNASDAQ · In Vitro & in Vivo Diagnostic Substances

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

95.6M

on 2026-06-30, from 90.5M on 2024-03-31 10-Q ↗

Newest

$200.0M

S-3 of 2026-02-24. 1 prospectus supplement filed under it since. S-3 ↗

None

No at-the-market programme on file in the last 30 months.

Warrants

The 10-Q filed 2026-07-31 is not read yet.

Cash

$115.2M

Operating cash flow was positive over the four quarters to 2026-06-30, so no quarters are counted. 10-Q ↗

Raised: 1 of its filings are not read yet.